Skip to content
Inciteful Med

Staging Systems & Prognosis

Last updated:

ALS progression is tracked using the ALSFRS-R scale, which measures physical function, alongside the King's and MiToS staging systems. These tools help your medical team monitor disease spread, predict your individual prognosis, and proactively plan for nutritional or breathing support.

Key Takeaways

  • • The ALSFRS-R is a standard 12-item questionnaire that measures physical function on a scale of 0 to 48.
  • • Doctors track the rate of decline in your ALSFRS-R score to predict your individual disease progression.
  • • The King's staging system tracks how ALS spreads across different body regions to help plan early interventions.
  • • The MiToS staging system monitors the loss of functional independence and is particularly useful in later disease stages.
  • • Proactively tracking your ALS stage helps you plan for feeding tubes or breathing support before emergencies arise.

As you navigate an ALS diagnosis, your medical team will use specific tools and “staging systems” to track how the disease is moving through your body. These measures are not meant to pin you to a rigid timeline, but rather to help your doctors provide the right care at the right time and help you plan for the future.

The Standard Measure: ALSFRS-R

The ALS Functional Rating Scale-Revised (ALSFRS-R) is the “gold standard” tool used in almost every ALS clinic and clinical trial [1][2]. It is a 12-item questionnaire that you or your doctor will complete at each visit.

  • How it works: You are rated from 0 (no function) to 4 (normal function) in 12 different activities, such as handwriting, walking, swallowing, and breathing [3][1].
  • The Score: The total score ranges from 0 to 48. A higher score means more preserved function [3].
  • Rate of Decline: Doctors often look at how quickly your score changes over time (known as the delta-FS). This rate of change is one of the best ways to predict how the disease may progress for you individually [4][5].

Comparing the Two Staging Systems

While the ALSFRS-R tracks your function, staging systems help doctors understand the burden of the disease and identify key milestones for intervention.

Feature King’s Staging System MiToS Staging System
Focus Anatomical Spread: Tracks how many regions of the body (arms, legs, bulbar) are affected [6]. Functional Loss: Tracks the loss of independence in specific ALSFRS-R domains [7][8].
The Stages Stages 1–3: Based on the number of body regions involved. Stage 4: Nutritional support (PEG) needed. Stage 5: Respiratory support (NIV) needed [6][9]. Stages 0–5: Ranges from no functional loss (0) to loss of function in all four domains (4), with Stage 5 representing death [7][8].
Best Use Best for early-to-mid disease and predicting the need for major clinical interventions [10][11]. Best for tracking late-stage disease and increasing levels of physical dependence [10][12].

Understanding Prognosis

While ALS is a progressive and life-limiting condition, the exact timeline varies drastically from person to person. Because the disease heavily impacts the muscles of the diaphragm and chest, your prognosis and life expectancy are closely tied to your respiratory function [13][14].

Staging systems like King’s and MiToS are empowering because they help you and your team stay proactive [14]. For example, reaching a certain stage may trigger a conversation about a feeding tube or breathing support before they become emergencies, which has been consistently shown to improve both survival and quality of life [15][8]. Your journey with ALS is unique, and these tools are simply maps to help you navigate it with the best possible support.

Frequently Asked Questions

What is the ALSFRS-R score?
The ALS Functional Rating Scale-Revised (ALSFRS-R) is a 12-item questionnaire that rates your physical function in activities like walking, swallowing, and breathing. Scores range from 0 to 48, with higher scores indicating more preserved function.
What is the difference between the King's and MiToS staging systems?
The King's system tracks the anatomical spread of ALS across different body regions, which helps predict the need for early interventions. The MiToS system focuses on the loss of functional independence and is often used to track late-stage disease.
How do doctors predict my ALS prognosis?
Doctors track how quickly your ALSFRS-R score changes over time, which is known as your rate of decline. This rate of change, along with monitoring your respiratory function, helps predict how the disease may progress for you individually.
When should I consider a feeding tube or breathing support for ALS?
Staging systems help your care team identify specific milestones so you can plan for interventions like a PEG feeding tube or non-invasive ventilation (NIV) before they become emergencies. Proactive planning has been shown to improve both survival and quality of life.

Questions for Your Doctor

  • • What is my current total score on the ALSFRS-R, and which specific areas (like breathing or swallowing) should we watch most closely?
  • • Does my current 'King's Stage' suggest that we should begin planning for a PEG tube or NIV in the near future?
  • • How quickly is my ALSFRS-R score changing, and what does that 'rate of decline' tell us about my prognosis?
  • • Are you using the MiToS system to track my functional independence, and how does that help us decide on home care needs?
  • • Can we review my scores from my last few visits to see if there are any patterns in how my symptoms are spreading?

Questions for You

  • • In which areas of my daily life (walking, speaking, dressing) have I noticed the most change since my last appointment?
  • • Am I noticing any new 'anatomical' spread, such as weakness moving from my legs to my arms, or changes in my voice?
  • • How do I feel about proactive interventions like a feeding tube or breathing machine as my stage progresses?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post-onset ΔFS for study design and medical practice.

    Ludolph AC, Corcia P, Desnuelle C, et al.

    Muscle & nerve 2024; (70(1)):36-41 doi:10.1002/mus.28101.

    PMID: 38712849
  2. 2

    A systematic review of digital technology to evaluate motor function and disease progression in motor neuron disease.

    Beswick E, Fawcett T, Hassan Z, et al.

    Journal of neurology 2022; (269(12)):6254-6268 doi:10.1007/s00415-022-11312-7.

    PMID: 35945397
  3. 3

    Integrating Multi-sensor Time-series Data for ALSFRS-R Clinical Scale Predictions in an ALS Patient Case Study.

    Marchal N, Janes WE, Earwood JH, et al.

    AMIA ... Annual Symposium proceedings. AMIA Symposium 2024; (2024()):788-797.

    PMID: 40417478
  4. 4

    Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study.

    Kjældgaard AL, Pilely K, Olsen KS, et al.

    BMC neurology 2021; (21(1)):164 doi:10.1186/s12883-021-02187-8.

    PMID: 33865343
  5. 5

    Motor cortical function determines prognosis in sporadic ALS.

    Shibuya K, Park SB, Geevasinga N, et al.

    Neurology 2016; (87(5)):513-20 doi:10.1212/WNL.0000000000002912.

    PMID: 27402895
  6. 6

    A standard operating procedure for King's ALS clinical staging.

    Balendra R, Al Khleifat A, Fang T, Al-Chalabi A

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2019; (20(3-4)):159-164 doi:10.1080/21678421.2018.1556696.

    PMID: 30773950
  7. 7

    Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach.

    Thakore NJ, Lapin BR, Kinzy TG, Pioro EP

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2018; (19(7-8)):483-494 doi:10.1080/21678421.2018.1484925.

    PMID: 30001159
  8. 8

    Milano-Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.

    He R, Zheng M, Lian L, Yao X

    Cells 2021; (10(5)) doi:10.3390/cells10051220.

    PMID: 34067647
  9. 9

    Diagnosis Particularities of Amyotrophic Lateral Sclerosis in an Elderly Patient.

    Marcu IR, Patru S, Bighea AC

    Current health sciences journal 2018; (44(1)):92-96 doi:10.12865/CHSJ.44.01.16.

    PMID: 30622763
  10. 10

    Comparison of the King's and MiToS staging systems for ALS.

    Fang T, Al Khleifat A, Stahl DR, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2017; (18(3-4)):227-232 doi:10.1080/21678421.2016.1265565.

    PMID: 28054828
  11. 11

    Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study.

    Ferraro D, Consonni D, Fini N, et al.

    European journal of neurology 2016; (23(9)):1426-32 doi:10.1111/ene.13053.

    PMID: 27238551
  12. 12

    The utility of ALS staging systems in a multi-ethnic patient cohort.

    Abdul Aziz NA, Toh TH, Loh EC, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2021; (22(5-6)):341-349 doi:10.1080/21678421.2021.1893336.

    PMID: 33726578
  13. 13

    Amyotrophic Lateral Sclerosis: New Perpectives and Update.

    Orsini M, Oliveira AB, Nascimento OJ, et al.

    Neurology international 2015; (7(2)):5885 doi:10.4081/ni.2015.5885.

    PMID: 26487927
  14. 14

    SIMpLE: A Mobile Cloud-Based System for Health Monitoring of People with ALS.

    Palumbo A, Ielpo N, Calabrese B, et al.

    Sensors (Basel, Switzerland) 2021; (21(21)) doi:10.3390/s21217239.

    PMID: 34770548
  15. 15

    Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.

    Paganoni S, Karam C, Joyce N, et al.

    NeuroRehabilitation 2015; (37(1)):53-68 doi:10.3233/NRE-151240.

    PMID: 26409693

This page explains ALS staging systems and prognosis tools for educational purposes. Always consult your neurologist or ALS care team for personalized information about your specific progression and care plan.

Stay up to date

Get notified when new research about Amyotrophic lateral sclerosis is published.

No spam. Unsubscribe anytime.